Fp7: Energy (Finland)

Description

Abstract

The Institute for Urban, Regional and Environmental Planning, Department of Urban Planning at the HafenCity University Hamburg, is interested in contributing to the development of a European research project proposal as a partner. We have experience (from previous European and national projects) and expertise in the fields of sustainable urban and regional development, territorial cohesion and regional competitiveness as well as metropolitan, urban and regional governance.

HafenCity University and the Department of Urban Planning

The HafenCity University in Hamburg (HCU) was founded in January 2006 and is the only university in Europe dedicated solely to teaching and research for the built environment and spatial development with the full range of disciplines necessary. The HCU therefore encompasses the disciplines of architecture, civil engineering, geomatics and urban and regional planning. The scientific and teaching methods and interests are creative, technical and social science based; they follow conceptual and applied approaches for analysing or designing buildings and spaces as well as its physical, social and political infrastructure. This comprehensive range of disciplines makes the HafenCity University to a unique place in Europe to find new approaches and solutions to the important and vexing problems facing our built world.

The Department of Urban Planning (former part of Hamburg-Harburg Technical University, founded in 1982) focuses on the sustainable development of cities and urban regions. This orientation requires profound knowledge within a variety of thematic areas, including urban morphological structures, social, economic and environmental mechanisms in urban development as well as the legal and political framework of planning and the strategies and processes of dealing with it. The Department of Urban Planning through (applied) research and outreach services aims to serve as a source for the investigation of issues and challenges facing urban bodies.

The Department of Urban Planning of the HafenCity University is composed of the following three institutes which cover this broad range of thematic fields:

− Institute for Urban, Regional and Environmental Planning
− Institute for Urban and Regional Economics and Sociology
− Institute for Urban Design and District Planning

Institute for Urban-, Regional- and Environmental Planning The Institute for Urban-, Regional- and Environmental Planning, Department of Urban Planning is one of the main promoters of an innovatively and internationally oriented research program of the HCU. Its focus lies on generating knowledge in the fields of sustainable urban and regional development as well as metropolitan, urban and regional governance. By addressing the main challenges facing urban development - like sustainable development and territorial cohesion, adaptation strategies to structural, demographic or climate change, metropolitan development, and support of regional competitiveness - priority is given to research, interdisciplinary studies and innovative solutions.

The Institutes combines the following professorships:

− Urban Planning and Regional Development

− Urban Ecology and Environmental Planning
− Infrastructure Planning and Urban Technology
− Law and Administration
− Geographic Information Systems (GIS)

Contact

We kindly ask you to contact us if you are planning or aware of any proposal in the mentioned areas where our contribution as German research partner is welcomed. For further information please do not hesitate to contact:

HafenCity University Hamburg

Department of Urban Planning
Institute for Urban-, Regional- und Environmental Planning
Schwarzenbergstr. 95 D
D-21073 Hamburg

Prof. Dr.-Ing. Jörg Knieling M.A.

Dipl.-Ing. Frank Othengrafen
Fon [phone]
Fax [phone]
[e-mail]
[e-mail]
www.hcu-hamburg.de
www.hcu-hamburg.de/stadtplanung

FP7: Health (France, 21.02.)

Funding Source/Programme

Health-2007-2.3.3-4

Description

A French SME wants to answer to the call Health-2007-2.3.3-4 (Innovative point-of care diagnostic tests for influenza; deadline 19 April 07), and wants either to find partners to create a consortium involved in the development of the innovative point-of-care diagnostic tests that can be used as an early warning system in surveillance programs for Avian influenza (on line monitoring by using PCR and/or microarray technologies) or to be part of an existing consortium.

The SME is an innovative biophotonic company devoted to electro-optical components, apparatus and systems for high performance genomic and post-genomic applications. Its core business is centred on the of fluorescence detection, particularly for biochips.

They are developing the new portable instruments which will integrate sample preparation, nucleic acid amplification, microarray hybridization and fluorescent readout in the same machine. They think that this technology (PCR and microarrays integrated in the same machine) is very well adapted for the rapid and simultaneous detection and identification of influenza viruses (typing and sub-typing).

Contact

Philippe Lenain

European projects consultant

Chambre de Commerce et d'Industrie de l'Essonne Service Innovation et Intelligence Économique 2, Cours Monseigneur Roméro BP 135
91004 Evry Cedex France
Tel: [phone]
Fax: [phone]
FP7: NMP & Health (Slovenia, 05.03.)

Funding Source/Programme

FP7: NMP & Health

Description

Lek, a Sandoz company is looking for a partner/coordinator for collaboration on FP7 projects. We are mainly, but not exclusively, interested in programme Cooperation in the areas Nanosciences,nanotechnologies, materials & new production technologies (NMP) or Health.

We are looking for partners from the EU and International Co-operation Partner Countries with strong RTD perspective. The fields of expertise we are looking for are:

Nanomaterials and Nanotechnologies
1. Coatings, composites, designed particles etc. that enable, control and facilitate solubility, solubility kinetics, different polymorphic forms, stability, controlled release profiles of active pharmaceutical ingredients.
2. Nanoparticles for (per)oral delivery of high potency drugs (formulation and enhanced absorption).
3. Particles with enhanced properties for per oral delivery of demanding active pharmaceutical ingredients.
4. Technologies for taste masking, solubilization, stabilization.
5. Particle design in supercritical fluids.
6. Semisynthetic biopharmaceuticals - modification synthetic chemical methods e.g. PEGylation, different PEG conjugates, native chemical ligation (NCL), expressed protein ligation, splicing.

Novel Drug delivery systems
7. Nanoparticulate drug carriers for pharmaceuticals and biopharmaceuticals.

New Analytical Approaches
8. In connection with above mentioned fields we are interested in development of Process Analytical Technologies with modern process analyzers and modern process analytical chemistry tools that will enable high quality production of nanotechnology based pharmaceutical products.

About Lek, a Sandoz company
Lek, a Sandoz company (http://www.lek.si/eng/), is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biopharmaceutical products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz's global markets. Lek d.d. employs about 2,820 people and achieved total sales of EUR 721 million in 2006.

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 active substances in over 5 000 forms worldwide. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (U.S.) and sells its products in more than 110 countries. In 2006, Sandoz employed around 21,000 people worldwide and posted sales of USD 6 billion.